1. Abdel-Wahab, M., et al., Aortic regurgitation after transcatheter aortic valve implantation: incidence and early outcome. Results from the German
transcatheter aortic valve interventions registry. Heart, 2011. 97(11): p.
899-906.
2. Amat-Santos, I.J., et al., Incidence, predictive factors, and prognostic value of new-onset atrial fibrillation following transcatheter aortic valve
implantation. J Am Coll Cardiol, 2012. 59(2): p. 178-88.
3. American College of, C., et al., ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol, 2006. 48(3): p. e1-148.
4. American College of Cardiology/American Heart Association Task Force on Practice, G., et al., ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of
Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation, 2006. 114(5): p. e84-231.
6. Baumgartner, H., et al., [2017 ESC/EACTS Guidelines for the management of valvular heart disease]. Kardiol Pol, 2018. 76(1): p. 1-62.
7. Baumgartner, H., et al., 2017 ESC/EACTS Guidelines for the Management of Valvular Heart Disease. Rev Esp Cardiol (Engl Ed), 2018. 71(2): p. 110.
8. Bleiziffer, S., et al., Survival after transapical and transfemoral aortic valve implantation: Talking about two different patient populations. The Journal of Thoracic and Cardiovascular Surgery. 138(5): p. 1073-1080. 2009
9. Bleiziffer, S., et al., Results of percutaneous and transapical transcatheter aortic valve implantation performed by a surgical team. Eur J Cardiothorac Surg, 2009. 35(4): p. 615-20; discussion 620-1.
10. Chen, S., et al., Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Prior Cardiac Surgery in the Randomized PARTNER 2A Trial.
JACC Cardiovasc Interv, 2018. 11(21): p. 2207-2216.
11. Chiam, P.T., et al., First transcatheter aortic valve implantation for severe pure aortic regurgitation in Asia. Singapore Med J, 2014. 55(2): p. 103-5.
13. Conradi, L., et al., Transcatheter aortic valve implantation versus surgical aortic valve replacement: a propensity score analysis in patients at high surgical risk. J Thorac Cardiovasc Surg, 2012. 143(1): p. 64-71.
14. Cribier, A., et al., Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description.
Circulation, 2002. 106(24): p. 3006-8.
15. Cribier, A., et al., Percutaneous transluminal valvuloplasty of acquired aortic stenosis in elderly patients: an alternative to valve replacement? Lancet, 1986. 1(8472): p. 63-7.
16. Cunningham, M.W., T cell mimicry in inflammatory heart disease. Mol Immunol, 2004. 40(14-15): p. 1121-7.
17. Deeb, G.M., et al., 3-Year Outcomes in High-Risk Patients Who Underwent Surgical or Transcatheter Aortic Valve Replacement. J Am Coll Cardiol, 2016.
67(22): p. 2565-74.
18. Delicce, A.V. and A.N. Makaryus, Physiology, Frank Starling Law, in StatPearls. 2020: Treasure Island (FL).
19. Eggebrecht, H. and R.H. Mehta, Transcatheter aortic valve implantation (TAVI) in Germany 2008-2014: on its way to standard therapy for aortic valve stenosis in the elderly? EuroIntervention, 2016. 11(9): p. 1029-33.
20. Faggiano, P., et al., Epidemiology and cardiovascular risk factors of aortic stenosis. Cardiovasc Ultrasound, 2006. 4: p. 27.
21. Feldman, T., Proceedings of the TCT: balloon aortic valvuloplasty appropriate for elderly valve patients. J Interv Cardiol, 2006. 19(3): p. 276-9.
22. Goldbarg, S.H., et al., Insights into degenerative aortic valve disease. J Am Coll Cardiol, 2007. 50(13): p. 1205-13.
23. Gotzmann, M., et al., Long-term outcome of patients with moderate and severe prosthetic aortic valve regurgitation after transcatheter aortic valve implantation. Am J Cardiol, 2012. 110(10): p. 1500-6.
24. Hall, J.E., & Guyton, A. C. , Guyton and Hall textbook of medical physiology.
25. Hamm, C.W., et al., [Diagnostic heart catheterization]. Clin Res Cardiol, 2008.
97(8): p. 475-512.
26. Hanzel, G.S., et al., Retrograde percutaneous aortic valve implantation for critical aortic stenosis. Catheter Cardiovasc Interv, 2005. 64(3): p. 322-6.
27. Hayashida, K., et al., Impact of CT-guided valve sizing on post-procedural aortic regurgitation in transcatheter aortic valve implantation.
EuroIntervention, 2012. 8(5): p. 546-55.
28. Holmes, D.R., Jr., et al., 2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement: developed in collaboration with the American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Failure Society of America, Mended Hearts, Society of Cardiovascular
Anesthesiologists, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. Ann Thorac Surg, 2012.
93(4): p. 1340-95.
29. Iung, B., et al., Decision-making in elderly patients with severe aortic stenosis:
why are so many denied surgery? Eur Heart J, 2005. 26(24): p. 2714-20.
30. Jilaihawi, H., et al., Cross-sectional computed tomographic assessment improves accuracy of aortic annular sizing for transcatheter aortic valve replacement and reduces the incidence of paravalvular aortic regurgitation. J Am Coll Cardiol, 2012. 59(14): p. 1275-86.
31. Karyofillis, P., et al., Conduction abnormalities after transcatheter aortic valve implantation. J Geriatr Cardiol, 2018. 15(1): p. 105-112.
32. Katayama, M. and H.P. Chaliki, Diagnosis and management of patients with
asymptomatic severe aortic stenosis. World J Cardiol, 2016. 8(2): p. 192-200.
33. Kaul, P., et al., Assessment of activity status and survival according to the Canadian Cardiovascular Society angina classification. Can J Cardiol, 2009.
25(7): p. e225-31.
34. Keeble, T.R., et al., Percutaneous balloon aortic valvuloplasty in the era of transcatheter aortic valve implantation: a narrative review. Open Heart, 2016. 3(2): p. e000421.
35. Koniari, I., et al., Incidence, pathophysiology, predictive factors and prognostic implications of new onset atrial fibrillation following transcatheter aortic valve implantation. J Geriatr Cardiol, 2018. 15(1): p. 50-54.
36. Kuck, K.H. and C. Hamm, Executive summary of the position paper of the German Cardiac Society on quality criteria for the implementation of transcatheter aortic valve implantation (TAVI. Eur Heart J, 2015. 36(6): p.
328-30.
37. Lancellotti, P., Grading aortic stenosis severity when the flow modifies the gradientvalve area correlation. Cardiovasc Diagn Ther, 2012. 2(1): p. 6-9.
38. Lapp, H., Das Herzkatheterbuch : Diagnostische und interventionelle Kathetertechniken. . Vol. 4. 2013, Stuttgart: Georg Thieme Verlag.
39. Leon, M.B., et al., Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med, 2016. 374(17): p. 1609-20.
40. Mack, M.J., et al., Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med, 2019. 380(18): p.
1695-1705.
41. Makkar, R.R., et al., Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement. N Engl J Med, 2020. 382(9): p. 799-809.
42. Mohler, E.R., 3rd, et al., Bone formation and inflammation in cardiac valves.
Circulation, 2001. 103(11): p. 1522-8.
43. Murray, M.I., et al., First experience with the new generation Edwards Sapien 3 aortic bioprosthesis: procedural results and short term outcome. J Interv Cardiol, 2015. 28(1): p. 109-16.
44. Novotny, R., et al., Failed TAVI in TAVI Implantation: TAVI Dislocation
Followed by Ensuing Surgical Graft Resection. Case Rep Cardiol, 2017. 2017:
p. 5086586.
45. Noyez, L., et al., Cardiac operative risk evaluation: The EuroSCORE II, does it make a real difference? Neth Heart J, 2012. 20(12): p. 494-8.
46. O'Brien, K.D., et al., Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis.
Arterioscler Thromb Vasc Biol, 1996. 16(4): p. 523-32.
47. Otto, C.M., et al., Three-year outcome after balloon aortic valvuloplasty.
Insights into prognosis of valvular aortic stenosis. Circulation, 1994. 89(2): p.
642-50.
48. Panagopoulou, V., et al., NTproBNP: an important biomarker in cardiac diseases. Curr Top Med Chem, 2013. 13(2): p. 82-94.
49. Pereira, J.J., et al., Survival after aortic valve replacement for severe aortic stenosis with low transvalvular gradients and severe left ventricular dysfunction. J Am Coll Cardiol, 2002. 39(8): p. 1356-63.
50. Pewsner, D., et al., Accuracy of electrocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: systematic review. BMJ, 2007. 335(7622): p. 711.
51. Pibarot, P. and J.G. Dumesnil, Low-flow, low-gradient aortic stenosis with
normal and depressed left ventricular ejection fraction. J Am Coll Cardiol,
2012. 60(19): p. 1845-53.
52. Pibarot, P. and J.G. Dumesnil, Paradoxical low-flow, low-gradient aortic stenosis: new evidence, more questions. Circulation, 2013. 128(16): p. 1729-32.
53. Pibarot, P., et al., Association of Paravalvular Regurgitation With 1-Year Outcomes After Transcatheter Aortic Valve Replacement With the SAPIEN 3 Valve. JAMA Cardiol, 2017. 2(11): p. 1208-1216.
54. Raphael, C., et al., Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure. Heart, 2007. 93(4): p. 476-82.
55. Reinohl, J., et al., In-hospital resource utilization in surgical and transcatheter aortic valve replacement. BMC Cardiovasc Disord, 2015. 15: p. 132.
56. Rosenkranz, S. and I.R. Preston, Right heart catheterisation: best practice and pitfalls in pulmonary hypertension. Eur Respir Rev, 2015. 24(138): p.
642-52.
57. Saia, F., et al., The role of percutaneous balloon aortic valvuloplasty as a bridge for transcatheter aortic valve implantation. EuroIntervention, 2011.
7(6): p. 723-9.
58. Sawaya, F.J., et al., Comparison between the SAPIEN S3 and the SAPIEN XT transcatheter heart valves: A single-center experience. World J Cardiol, 2016.
8(12): p. 735-745.
59. Schwarz, F., et al., The effect of aortic valve replacement on survival.
Circulation, 1982. 66(5): p. 1105-10.
60. Schymik, G., et al., European experience with the second-generation Edwards SAPIEN XT transcatheter heart valve in patients with severe aortic stenosis: 1-year outcomes from the SOURCE XT Registry. JACC Cardiovasc Interv, 2015.
8(5): p. 657-69.
61. Seldinger, S.I., Catheter replacement of the needle in percutaneous
arteriography. A new technique. Acta Radiol Suppl (Stockholm), 2008. 434:
p. 47-52.
62. Sieber, F.E., Postoperative delirium in the elderly surgical patient.
Anesthesiol Clin, 2009. 27(3): p. 451-64, table of contents.
63. Sinning, J.M., et al., Next-generation transcatheter heart valves: current trials in Europe and the USA. Methodist Debakey Cardiovasc J, 2012. 8(2): p. 9-12.
64. Smith, C.R., et al., Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med, 2011. 364(23): p. 2187-98.
65. Stewart, B.F., et al., Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol, 1997. 29(3): p. 630-4.
66. Stortecky, S., et al., Transcatheter aortic valve implantation: the procedure.
Heart, 2012. 98 Suppl 4: p. iv44-51.
67. Sullivan, P.G., J.D. Wallach, and J.P. Ioannidis, Meta-Analysis Comparing Established Risk Prediction Models (EuroSCORE II, STS Score, and ACEF Score) for Perioperative Mortality During Cardiac Surgery. Am J Cardiol, 2016. 118(10): p. 1574-1582.
68. Svensson, L.G., et al., A comprehensive review of the PARTNER trial. J Thorac Cardiovasc Surg, 2013. 145(3 Suppl): p. S11-6.
69. Taniguchi, T., et al., Sudden Death in Patients With Severe Aortic Stenosis:
Observations From the CURRENT AS Registry. J Am Heart Assoc, 2018. 7(11).
70. Thaden, J.J., V.T. Nkomo, and M. Enriquez-Sarano, The global burden of
aortic stenosis. Prog Cardiovasc Dis, 2014. 56(6): p. 565-71.
71. Thourani, V.H., et al., Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis.
Lancet, 2016. 387(10034): p. 2218-25.
72. Thyregod, H.G., et al., Transcatheter Versus Surgical Aortic Valve
Replacement in Patients With Severe Aortic Valve Stenosis: 1-Year Results From the All-Comers NOTION Randomized Clinical Trial. J Am Coll Cardiol, 2015. 65(20): p. 2184-94.
73. Treede, H., et al., JenaValve. EuroIntervention, 2012. 8 Suppl Q: p. Q88-93.
74. Tse, L., et al., Postoperative delirium following transcatheter aortic valve implantation: a historical cohort study. Can J Anaesth, 2015. 62(1): p. 22-30.
75. Ussia, G.P., et al., Transcatheter aortic bioprosthesis dislocation: technical aspects and midterm follow-up. EuroIntervention, 2012. 7(11): p. 1285-92.
76. Vahanian, A., et al., Guidelines on the management of valvular heart disease:
The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J, 2007. 28(2): p. 230-68.
77. Vahanian, A. and B. Iung, The new ESC/EACTS guidelines on the management of valvular heart disease. Arch Cardiovasc Dis, 2012. 105(10): p. 465-7.
78. Walther, T., et al., Transapical aortic valve implantation: step by step. Ann Thorac Surg, 2009. 87(1): p. 276-83.
79. Walther, T., et al., One-year interim follow-up results of the TRAVERCE trial:
the initial feasibility study for trans-apical aortic-valve implantation. Eur J Cardiothorac Surg, 2011. 39(4): p. 532-7.
80. Walther, T., et al., PREVAIL TRANSAPICAL: multicentre trial of transcatheter aortic valve implantation using the newly designed bioprosthesis (SAPIEN-XT) and delivery system (ASCENDRA-II). Eur J Cardiothorac Surg, 2012.
42(2): p. 278-83; discussion 283.
81. Webb, J., et al., Multicenter evaluation of a next-generation
balloon-expandable transcatheter aortic valve. J Am Coll Cardiol, 2014. 64(21): p.
2235-43.
82. Webb, J.G., et al., A new transcatheter aortic valve and percutaneous valve delivery system. J Am Coll Cardiol, 2009. 53(20): p. 1855-8.
83. Wendler, O., et al., SOURCE 3 Registry: Design and 30-Day Results of the European Postapproval Registry of the Latest Generation of the SAPIEN 3 Transcatheter Heart Valve. Circulation, 2017. 135(12): p. 1123-1132.
84. Wohrle, J., et al., Transfemoral Aortic Valve Implantation with the New Edwards Sapien 3 Valve for Treatment of Severe Aortic Stenosis-Impact of Valve Size in a Single Center Experience. PLoS One, 2016. 11(3): p.
e0151247.
85. Ye, J., et al., Transapical transcatheter aortic valve implantation: 1-year outcome in 26 patients. J Thorac Cardiovasc Surg, 2009. 137(1): p. 167-73.
86. Yoshioka, N., et al., Do radial arterial pressure curves have diagnostic validity for identify severe aortic stenosis? J Anesth, 2010. 24(1): p. 7-10.
87. Zahn, R., et al., There are two sides to everything: two case reports on
sequelae of rescue interventions to treat complications of transcatheter aortic valve implantation of the Medtronic CoreValve prosthesis. Clin Res Cardiol, 2010. 99(9): p. 579-85.
88. Zhao, A., et al., A meta-analysis of transfemoral versus transapical transcatheter aortic valve implantation on 30-day and 1-year outcomes.
